Abstract 646P
Background
Creatine Kinase B (CKB) was identified as a driver of RASm mCRC. CKB generates ATP from phosphocreatine (PCr), which is imported by SLC6A8. Ompenaclid depletes PCr and ATP resulting in tumor cell apoptosis. In a phase 1a study, ompenaclid monotherapy showed objective anti-tumor activity in RASm mCRC without dose-limiting toxicities (DLTs).
Methods
Objectives of this ongoing phase 1b/2 study are evaluation of safety, PK/PD and efficacy of ompenaclid + FOLFIRI/BEV in 2L mCRC. Eligible pts had disease progression after a 1L oxaliplatin-containing regimen.
Results
Enrollment as of 28Apr2023, 35 pts (22 KRASm, 3 NRASm, 10 RAS-wt) in the Dose Escalation/Expansion cohorts receiving 2400mg BID (n=14) or 3000mg BID (n=21); all pts received FOLFIRI/BEV. No DLTs were observed in Dose Escalation and a MTD was not reached. Across safety-evaluable pts (n=33), the most common treatment emergent AEs Gr≤2 were nausea (50%), diarrhea (44%); Gr≥3 were neutropenia (15%), abdominal pain (11%), diarrhea (11%), fatigue (11%). The AE profile is similar to FOLFIRI/BEV alone, demonstrating good combinability. At both ompenaclid doses, systemic exposure was comparable and resulted in up to a 48X increase in urine creatine, suggesting robust target inhibition. The ORR in 17 RASm and 10 RAS-wt evaluable pts was 41% (6 confirmed PRs, 1 unconfirmed PR) and 20% (2 unconfirmed PRs), respectively. Five RASm pts are pending 1st scan and not yet evaluable. PRs were observed in pts with diverse KRASm (G13D [2 pts], G12V [2 pts], G12D, G12S and pG10dup). For RASm pts, mPFS was 11.8M and mOS was 19.1M, and for RAS-wt pts, mPFS was 7.5M and mOS was 14.5M.
Conclusions
At the evaluated dose levels, ompenaclid + FOLFIRI/BEV was well tolerated and induced potent inhibition of the target SLC6A8. Encouraging efficacy was observed in pts with RASm mCRC, with a response rate exceeding that expected with SOC. This preferential RASm activity is consistent with preclinical and phase 1a data. There is a high unmet need for a safe and combinable oral pan-RASm therapy in mCRC. Recruitment of RASm pts continues and a randomized controlled trial in 2L RASm mCRC is planned.
Clinical trial identification
NCT03597581.
Editorial acknowledgement
Lesley Skingley, Bexon Clinical Consulting.
Legal entity responsible for the study
Inspirna, Inc.
Funding
Inspirna, Inc.
Disclosure
D.R. Spigel: Financial Interests, Institutional, Other, Consulting: Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, Curio Science, EMD Serono, Evidera, Exelixis, Genentech/Roche, GSK, Intellisphere, Ipsen Biopharmaceuticals, Janssen, Jazz Pharmaceuticals, Lilly, Mirati Therapeutics, Molecular Templates, Monte Rosa Therapeutics, Novartis, Pfizer, Puma Biotechnology, Regeneron, Sanofi-Aventis; Financial Interests, Institutional, Research Grant, Serve as PI: Amgen, Aeglea Biotherapeutics, Agios, Bayer, Arrys Therapeutics, Astellas, AstraZeneca, BeiGene, BIND Therapeutics, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celldex Therapeutics, Clovis, Daiichi Sankyo, Eisai, Lilly, EMD Serono, Genentech/Roche, G1 Therapeutics, Gilead Sciences, ImClone Systems, GSK, GRAIL, Hutchinson MediPharma, Ipsen, Janssen, Loxo, MacroGenics, MedImmune, Merck, Nektar, PTC Therapeutics, Neon Therapeutics, Novartis, Novocure, Rgenix, SeaGen, Taiho Oncology, Tarveda, Verastem, Tizona Therapeutics, Transgene, UT Southwestern, Arcus Biosciences, Oncologie, Molecular Template, Cyteir Therapeutics, BioNTech, Apollomics, Pure Tech Health, Elevation Oncology, Repare Therapeutics, Razor Genomics, Denovo Biopharma, Erasca, Kronos Bio, Zai Laboratory, Faeth Therapeutics, Ascendis Pharma, Lyell Immunopharma, Synthekine, Shenzhen Chipscreen Biosciences. M. Fakih: Financial Interests, Personal, Advisory Role: AstraZeneca, Bayer Corporation, Bristol Myers Squibb, Eisai Oncology, Entos, Merck, Roche/Genentech; Financial Interests, Personal, Advisory Board: Mirati, Nouscom; Financial Interests, Institutional, Research Grant: Genentech, Verastem. A.S. Paulson: Financial Interests, Personal, Invited Speaker, Medical education, non-branded, industry sponsored: Ideo Oncology; Financial Interests, Personal, Advisory Board: Amgen, Bristol Myers Squibb, Eisai, Ipsen, Incyte, Exelixis, AAA, Pfizer, QED, Lilly, Mirati, Hutchinson, Astellas; Financial Interests, Personal, Stocks/Shares: Alexion, Actinium, Aptose; Financial Interests, Invited Speaker: Ipsen, Hutchinson, Bristol Myers Squibb, Exelixis, Hutchinson med, Taiho, Lilly, AstraZeneca, Incyte, Seattle Genetics, Deciphera, Tempus, Zentalis, G1 therapeutics, Merck, Camurus, Novartis, Surface, Relay Therapeutics; Financial Interests, Institutional, Invited Speaker: Mirati, Bayer. R. Wasserman: Financial Interests, Personal, Advisory Board: Secotral Asset Management, Sixty Degree; Financial Interests, Personal, Officer: Inspirna; Financial Interests, Personal, Stocks/Shares: Inspirna, Sectoral Asset Management, Sixty Degree, Northern Biologics, Thatch Health; Financial Interests, Personal, Invited Speaker: Inspirna; Financial Interests, Personal, Royalties: Northern Biologics. All other authors have declared no conflicts of interest.
Resources from the same session
769P - Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study
Presenter: Joanneke Overbeek
Session: Poster session 11
770P - Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Presenter: Maria Jesus Rubio Perez
Session: Poster session 11
771P - Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets
Presenter: Ugo De Giorgi
Session: Poster session 11
773P - Real-world results of homologous recombination deficiency testing: Comparison between two methods on 2,655 ovarian cancer patients in Spain
Presenter: Conxi Lazaro
Session: Poster session 11
774P - CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
Presenter: Felix Blanc-Durand
Session: Poster session 11
775P - A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial
Presenter: David SP Tan
Session: Poster session 11
776P - Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study
Presenter: Daria Afenteva
Session: Poster session 11
777P - Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models
Presenter: Daisuke Shintani
Session: Poster session 11
778P - Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression via disrupted ribosomal biogenesis
Presenter: Chyong-Huey Lai
Session: Poster session 11
779P - Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Presenter: Carmen Garcia Duran
Session: Poster session 11